Combined Assays of Tumor Marker CEA, CA153, SCC and CY211 for Differential Diagnosis of Pleural Effusion

王谮,张斯为,高泉,陈小东,张静

DOI: https://doi.org/10.3781/j.issn.1000-7431.2002.04.022

2002-01-01

Tumor

Abstract:Objective To study the clinical significance of tumor markers combined assay in the differential diagnosis of. pleural effusion. Methods 79 serum and hydrothorax samples were collected from 79 in-patients with pleural effusion. Among them, 35 patients were suffered with malignant pleural effusion and 44 patients with benign pleural effusion. The concentration of CEA, CA153, SCC and CY211 was determined by immunoradiometric assay. Results In malignant pleural effusion group, the positive rates of serum CEA, CA153, SCC and CY211 were 58.82%?70.59%?9.09% and 54.20% respectively, the positive rates of hydrothorax CEA, CA153, SCC and CY211 were 75.76%?70.67%?25.93% and 96.67% respectively. Among them,CEA,CA153 and CY211 in malignant group were significantly higher than that in benign pleural effusion group ( P 0.02).So as did of the concentration. The sensitivity of combined assay with serum CA153+CY211 in diagnosing malignant pleural effusion was 94.28%, with the specificity of 76.93%. Conclusion Tumor markers of CEA,CA153 and CY211 have high clinical values in the differential diagnosis of pleural effusion. The combined assay with CA153+CY211 is recommended.